Advertisement

Topics

Spinocerebellar Ataxias - Pipeline Review, H1 2015

02:29 EDT 22 Jul 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Spinocerebellar Ataxias - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-16. This 47-page report is available in PDF from $2000.

Spinocerebellar Ataxias - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Spinocerebellar Ataxias - Pipeline Review, H1 2015’, provides an overview of the Spinocerebellar Ataxias’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Spinocerebellar Ataxias, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinocerebellar Ataxias and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxias
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Spinocerebellar Ataxias and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Spinocerebellar Ataxias products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Spinocerebellar Ataxias pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Spinocerebellar Ataxias Overview 6
Therapeutics Development 7
Pipeline Products for Spinocerebellar Ataxias - Overview 7
Pipeline Products for Spinocerebellar Ataxias - Comparative Analysis 8
Spinocerebellar Ataxias - Therapeutics under Development by Companies 9
Spinocerebellar Ataxias - Therapeutics under Investigation by Universities/Institutes 10
Spinocerebellar Ataxias - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Spinocerebellar Ataxias - Products under Development by Companies 14
Spinocerebellar Ataxias - Products under Investigation by Universities/Institutes 15
Spinocerebellar Ataxias - Companies Involved in Therapeutics Development 16
Baxter International Inc. 16
Bioblast Pharma Ltd. 17
Kissei Pharmaceutical Co., Ltd. 18
Vybion, Inc. 19
Spinocerebellar Ataxias - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
epoetin alfa - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
immune globulin (human) - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
INT-41 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
KPS-0373 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
RNAi Gene Therapy for Machado-Joseph Disease - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure, Post Cardiopulmonary Resuscitation and Neurodegenerative Diseases - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
trehalose - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Spinocerebellar Ataxias - Recent Pipeline Updates 39
Spinocerebellar Ataxias - Dormant Projects 43
Spinocerebellar Ataxias - Dormant Projects 43
Spinocerebellar Ataxias - Product Development Milestones 44
Featured News & Press Releases 44
Mar 30, 2015: BioBlast Pharma Announces Positive in vivo Preclinical Proof-of-Concept Results of Its Cabaletta Platform in Spinocerebellar Ataxia Type 3 44
Nov 19, 2014: Bio Blast Pharma Receives Orphan Drug Designation From U.S. FDA for Cabaletta for the Treatment of Spinocerebellar Ataxia Type 3 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

For more information open Spinocerebellar Ataxias - Pipeline Review, H1 2015.

SKU: GMDHC6798IDB

Original Article: Spinocerebellar Ataxias - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Spinocerebellar Ataxias - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...